Analyst Price Target is $15.78
▲ +94.31% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for BioCryst Pharmaceuticals in the last 3 months. The average price target is $15.78, with a high forecast of $30.00 and a low forecast of $10.00. The average price target represents a 94.31% upside from the last price of $8.12.
Current Consensus is
Buy
The current consensus among 9 polled investment analysts is to buy stock in BioCryst Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.
Read More